Merilog is expected to be available in July 2025, and Sanofi will provide Merilog to patients for $35 or less for a 30-day ...

US companies eagerly offshored their supply chains to drive down costs and boost profits. But today, the world economy is a ...

Donald Trump's proposal to impose a 25% or more tariff on pharmaceutical imports into the United States holds significant ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

The company relies on its key generic drugs in oncology and immunology therapies for sales in the region, which rose 28 per ...

U.S. President Donald Trump said on Tuesday he intends to impose a "25% or higher" levies on semiconductors and ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® ...

First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

The approval was based on a comprehensive clinical data package, which included a single phase 1 trial and a phase 3 trial.

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

The U.S. stands at a crossroads in light of rising drug prices and it is unclear what the future will hold in answer to the ...